#USA #New York #Cancer Care #Nucs AI #AI Theranostics

Nucs AI's Medical Advisory Board: A Leap Forward in AI-Driven Theranostics

Nucs AI, a pioneering company at the forefront of artificial intelligence in the healthcare sector, has made a significant announcement regarding the establishment of its Medical Advisory Board (MAB). This initiative is aimed at expediting the adoption of AI-driven theranostics technology primarily targeted at the oncology field. The formation of this board brings together a diverse team of clinical leaders who possess extensive expertise in various disciplines including radiology, nuclear medicine, oncology, and clinical research.

As the landscape of cancer treatment continues to evolve, particularly with the rise of radioligand therapies and other theranostic methodologies, the necessity for effective measurement of treatment responses and disease behavior over time becomes paramount. The integration of AI in clinical decision-making processes emphasizes an even greater need for clinical oversight and the generation of robust evidence that is in harmony with real-world healthcare pathways.

Nucs AI's motivation for forming the Medical Advisory Board centers around the objective of ensuring that its technological advancements remain closely aligned with clinical practices as it seeks to gain broader validation and implementation. The company is deeply committed to fostering informed and personalized treatment choices by enhancing clinicians' understanding of patients’ disease responses over time.

According to Nijat Ahmadov, CEO of Nucs AI, the guidance provided by clinical insight and real-world experience is vital as theranostic practices and AI become integrated into nuclear medicine and oncology care. Ahmadov stated, “Our Medical Advisory Board reflects our commitment to building technology that earns trust through evidence, rigor, and close partnership with the clinicians who will ultimately use it.”

The MAB will play an integral role in shaping Nucs AI's clinical strategy, influencing study design decisions and promoting the responsible incorporation of imaging-based AI solutions within nuclear medicine. The board members possess an array of viewpoints derived from their extensive experiences in academic research, clinical trials, hospital-based care, and pharmaceutical development. As Nucs AI progresses with its technology and evidence-generation activities, this board will provide continuous guidance to ensure the alignment of its initiatives with patient needs and the dynamic realities of clinical workflows.

Members of the Medical Advisory Board

The founding members of the Medical Advisory Board include prominent figures in the field:

• - Jeremie Calais, MD, PhD - Serving as the Director of the Clinical Research Program of Nuclear Medicine and Theranostics at UCLA, he also holds the position of Associate Professor within the Ahmanson Translational Theranostics Division in the Department of Molecular and Medical Pharmacology.

• - A. Omer Nawaz, PhD, DABR - An Independent Scientific Advisor, Nawaz leads the Theranostics and Radiation Science division at AstraZeneca's Oncology Research and Development.

• - Francesco Ceci, MD, PhD - Ceci is the Director of Nuclear Medicine and Theranostics at the IEO European Institute of Oncology in Milan, and he also serves as an Associate Professor in the Department of Oncology at the University of Milan.

• - Murray Becker, MD, PhD, FACR - Becker is affiliated with the University Radiology Group and holds the profile of Associate Clinical Professor at Rutgers Robert Wood Johnson Medical School.

The advent of this Medical Advisory Board epitomizes a pivotal progression for Nucs AI as it ventures deeper into its technological endeavors while preparing for upcoming clinical, regulatory, and commercial activities. The board's evolution will ensure that Nucs AI's growth is congruent with the requirements of patients, clinical operations, and the evolving landscape of cancer therapy.

About Nucs AI

Nucs AI is on a mission to revolutionize precision oncology through its integration of AI-powered imaging and predictive analytics. The company's suite of innovative solutions, including DeepPSMA, SelectPSMA, and TrackPSMA, aims to automate the processes of detection, staging, and evaluating treatment responses for prostate cancer. This empowers clinicians to make quicker, more informed treatment decisions. With collaborations that include prestigious institutions such as Johns Hopkins University, Nucs AI is setting benchmarks in the realm of molecular imaging and establishing a new paradigm for AI-assisted diagnostics. For further details, please visit www.nucs.ai.